Market Newsdesk

—
First
Dedicated
Clinical Tria
l of
an
Anti-CD47 Antibody in
Multiple Myeloma
—

—
At ASH 2020, New
Pre
clinical Data
Presented
on AO-176 in 
Multi
ple
Myeloma —

BRISBANE, Calif. and ST. LOUIS, Dec. 07, 2020 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that the first patient has been dosed in a new Phase 1/2 clinical trial for AO-176 in relapsed/refractory multiple myeloma. AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential binding to tumor versus normal cells. In preclinical myeloma models involving large tumors, AO-176 has demonstrated promising activity as a single agent as well as in combination with standard approved therapies used to treat this disease.

“We are excited to begin dosing patients in our second clinical trial for AO-176,” said Julie Hambleton, M.D., Interim President and Chief Executive Officer of Arch Oncology. “This is an important milestone for AO-176 and for patients as this is the first dedicated trial of an anti-CD47 antibody exclusively in patients with multiple myeloma. In our first clinical trial of AO-176, we saw encouraging anti-tumor activity as a single agent in patients with solid tumors and we are excited to evaluate our therapy for patients with multiple myeloma. With this second clinical trial initiated, we are making progress advancing AO-176 for both solid tumors and hematologic malignancies as we aim to deliver new cancer treatments to broader groups of patients.”

Paul Richardson, M.D., Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Co-Principal Investigator for this clinical trial, commented, “Research shows AO-176 has a highly-differentiated mechanism among this promising new class of anti-CD47 agents. We look forward to evaluating AO-176 as a monotherapy and in combination with standard therapies for patients with relapsed and refractory multiple myeloma. Patients who have progressed despite multiple lines of prior treatment urgently need new treatment options, and we are eager to assess the safety and preliminary efficacy profile of this exciting novel agent.”

This open-label, multi-center, dose-escalation Phase 1/2 trial is evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AO-176 in patients with relapsed/refractory multiple myeloma. Up to 100 patients whose disease has progressed following at least three prior lines of treatment will be enrolled. In Phase 1, patients enrolled in up to four dose-escalation cohorts will receive AO-176 monotherapy. Next, patients will receive AO-176 in combination with dexamethasone and bortezomib. Then, in Phase 2, patients will receive a recommended dose of AO-176 in combination with dexamethasone and bortezomib to evaluate the safety and preliminary efficacy of this combination.

Parameswaran Hari, MD, MRCP, MS, Chief of the Division of Hematology and Oncology in the Department of Medicine and Professor at Medical College of Wisconsin and Principal Investigator for this clinical trial, added, “We are pleased to dose the first patient in this new multiple myeloma clinical trial. As we treat patients with multiple myeloma, an incurable disease for many patients, we look forward to evaluating AO-176 as a potential new treatment option for patients living with this disease. Given the mechanism and profile of AO-176, we envision additional future combinations with AO-176 to evaluate as future treatments for patients.” 

Recent
Preclinical Data Presentation
s
on AO-176 in Multiple Myeloma

Event: ASH Annual Meeting & Exposition 2020
Date: December 5, 2020 7:00 am – 3:30 pm PT
Abstract Title: Pre-clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia
Date: December 6, 2020 7:00 am – 3:30 pm PT
Abstract Title: AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma as a Single Agent and in Combination With Approved Therapeutics

About
AO-176
AO-176 is a humanized anti-CD47 IgG2 antibody with a potential best-in-class profile. AO-176 is highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class of innate checkpoint inhibitors. AO-176 works by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, AO-176 has additional mechanisms, including directly killing tumor cells and inducing DAMPs (Damage Associated Molecular Patterns), resulting in Immunogenic Cell Death. Importantly, AO-176 binds preferentially to tumor cells, instead of to normal cells, and binds even more potently to tumors in their acidic microenvironment (low pH). Publications and presentations on AO-176 can be found at https://archoncology.com/our-pipeline/sci-pubs/.

AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies. In a Phase 1 trial in solid tumors, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity when administered as a single agent. Additional information about these trials may be found at www.clinicaltrials.gov using the trial identification number NCT03834948 (solid tumors) or NCT04445701 (multiple myeloma).

About
Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer. For more information please visit www.archoncology.com.

Contact:
Amy Figueroa, CFA
For Arch Oncology
[email protected]

– Special meeting of stockholders to approve proposed business combination with Canoo Holdings Ltd. to be held on December 21, 2020 –

– Record date for the special meeting will be October 27, 2020 –

– Upon closing, combined company stock and warrants will trade under “GOEV” and “GOEVW” ticker symbols –

– Canoo will reveal its Multi-Purpose Delivery Vehicle on December 17, 2020 –

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) — Hennessy Capital Acquisition Corp. IV (NASDAQ: HCAC, HCACW, HCACU) (“HCAC”) today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared effective its registration statement on Form S-4 (File No. 333-248923) (as amended, the “Registration Statement”), which includes a definitive proxy statement/prospectus in connection with HCAC’s special meeting of stockholders (the “Special Meeting”) to consider the previously announced proposed business combination (the “Business Combination”) with Canoo Holdings Ltd. (“Canoo”). Additionally, HCAC today announced that it has set a record date of October 27, 2020 (the “Record Date”) and a meeting date of December 21, 2020 for its Special Meeting.

Daniel Hennessy, Chairman & Chief Executive Officer of HCAC said, “We are pleased to reach this significant milestone in the transaction process, which will lead to Canoo becoming a public company upon approval by HCAC shareholders. This transaction has enabled Canoo to accelerate key initiatives, including pulling forward its all electric B2B (business to business) multi-purpose delivery vehicle which will be revealed on December 17, 2020.” 

Hennessy continued, “Since announcing the transaction, Canoo has seen substantial growth in consumer demand and significant interest from potential partners in its proprietary market leading EV platform and underlying technologies. Canoo is efficiently allocating capital by leveraging this platform and has identified new opportunities significantly increasing its TAM (total addressable market) in both B2B and B2C (business to customer) end markets. We have never been more excited about the future of Canoo and look forward to closing our planned merger later in December.”

HCAC’s stockholders of record at the close of business on the Record Date are entitled to receive notice of the Special Meeting and to vote the shares of common stock of HCAC owned by them at the Special Meeting. In light of the COVID-19 pandemic and to support the well-being of HCAC’s stockholders and partners, the Special Meeting will be completely virtual. In connection with the Special Meeting, HCAC’s stockholders that wish to exercise their redemption rights must do so no later than 5:00 p.m. Eastern Time on December 17, 2020 by following the procedures specified in the definitive proxy statement/prospectus for the Special Meeting. There is no requirement that stockholders affirmatively vote for or against the Business Combination at the Special Meeting in order to redeem their shares for cash.

As announced previously, the Business Combination will result in Canoo becoming a direct wholly-owned subsidiary of HCAC. HCAC will be renamed “Canoo Inc.” upon completion of the Business Combination, and its common stock and warrants are expected to be traded on the Nasdaq Global Select Market under the new symbols “GOEV” and “GOEVW”, respectively. At the closing of the Business Combination, each HCAC unit will separate into its components consisting of one share of HCAC common stock and three-quarters of one warrant and, as a result, will no longer trade as a separate security.

The Record Date determines the holders of HCAC’s common stock entitled to receive notice of and to vote at the Special Meeting, and at any adjournment or postponement thereof, whereby stockholders will be asked to approve and adopt the Business Combination, and such other proposals as disclosed in the definitive proxy statement included in the Registration Statement. If the Business Combination is approved by HCAC stockholders, HCAC anticipates closing the Business Combination shortly after the Special Meeting, subject to the satisfaction or waiver (as applicable) of all other closing conditions.

The Special Meeting will take place at 10:00 a.m., Eastern Time, on December 21, 2020 via a virtual meeting at the following address: https://www.cstproxy.com/hennessycapiv/sm2020. HCAC stockholders entitled to vote at the Special Meeting will need the 12-digit meeting control number that is printed on their respective proxy cards to enter the Special Meeting. HCAC recommends that its stockholders wishing to vote at the Special Meeting log in at least 15 minutes before the Special Meeting starts. Please note that HCAC stockholders will not be able to attend the Special Meeting in person. HCAC encourages its stockholders entitled to vote at the Special Meeting to vote their shares via proxy in advance of the Special Meeting by following the instructions on the proxy card.

A list of HCAC stockholders entitled to vote at the Special Meeting will be open to the examination of any HCAC stockholder, for any purpose germane to the Special Meeting, during regular business hours for a period of ten calendar days before the Special Meeting.

About Hennessy Capital Acquisition Corp.
IV

Hennessy Capital Acquisition Corp. IV is a special purpose acquisition company (or SPAC) which raised $300 million in its IPO in March 2019 and is listed on the Nasdaq Stock Market (NASDAQ: HCAC, HCACU, HCACW). HCAC was founded by Daniel J. Hennessy to pursue an initial business combination, with a specific focus on businesses in the industrial, technology and infrastructure sectors. For more information, please visit www.hennessycapllc.com.

Additional Information About the Proposed Business Combination and Where
t
o Find It

In connection with the Business Combination, HCAC filed the Registration Statement with the SEC, which includes the definitive proxy statement to be distributed to holders of HCAC’s common stock in connection with HCAC’s solicitation of proxies for the vote by HCAC’s stockholders with respect to the Business Combination and other matters as described in the Registration Statement and a prospectus relating to the offer of the securities to be issued to the equity holders of Canoo in connection with the Business Combination. The Registration Statement was declared effective by the SEC on December 4, 2020 and the definitive proxy statement/prospectus and other relevant documents have been mailed to HCAC’s stockholders as of the Record Date. HCAC’s stockholders and other interested persons are advised to read the definitive proxy statement / prospectus, in connection with HCAC’s solicitation of proxies for the Special Meeting to be held to approve, among other things, the Business Combination, because these documents contain important information about HCAC, Canoo and the Business Combination. Stockholders may also obtain a copy of the definitive proxy statement/prospectus, as well as other documents filed with the SEC regarding the Business Combination and other documents filed with the SEC by HCAC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to Nicholas A. Petruska, Executive Vice President, Chief Financial Officer, 3415 N. Pines Way, Suite 204, Wilson, Wyoming 83014 or by telephone at (307) 201-1903.

Participants in the Solicitation

HCAC, Canoo and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from HCAC’s stockholders in connection with the Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of HCAC’s stockholders in connection with the Business Combination, including a description of their direct and indirect interests, is set forth in the Registration Statement filed with the SEC. You can find more information about HCAC’s directors and executive officers in the Registration Statement. You may obtain free copies of these documents from the sources indicated above.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expectations and timing related to commercial product launches, ability to accelerate Canoo’s go-to-market strategy and capitalize on commercial opportunities, potential benefits of the transaction and the potential success of Canoo’s go-to-market strategy, and expectations related to the terms and timing of completing the transaction. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Canoo’s and HCAC’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Canoo and HCAC. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the Business Combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Business Combination or that the approval of the stockholders of HCAC or Canoo is not obtained; failure to realize the anticipated benefits of the Business Combination; risks relating to the uncertainty of the projected financial information with respect to Canoo; risks related to the rollout of Canoo’s business and the timing of expected business milestones and commercial launch; risks related to future market adoption of Canoo’s offerings; risks related to Canoo’s go-to-market strategy and subscription business model; the effects of competition on Canoo’s future business; the amount of redemption requests made by HCAC’s public stockholders; the ability of HCAC or the combined company to issue equity or equity-linked securities in connection with the Business Combination or in the future, and those factors discussed in HCAC’s final prospectus filed on March 4, 2019, Annual Report on Form 10-K for the fiscal year ended December 31, 2019, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and the Registration Statement, and the definitive proxy statement/prospectus contained therein, in each case, under the heading “Risk Factors,” and other documents of HCAC filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither HCAC nor Canoo presently know or that HCAC and Canoo currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect HCAC’s and Canoo’s expectations, plans or forecasts of future events and views as of the date of this press release. HCAC and Canoo anticipate that subsequent events and developments will cause HCAC’s and Canoo’s assessments to change. However, while HCAC and Canoo may elect to update these forward-looking statements at some point in the future, HCAC and Canoo specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing HCAC’s and Canoo’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Contact
s
:

Hennessy Capital Acquisition Corp. IV
Nicholas A. Petruska, Executive Vice President and CFO
(307) 201-1903
[email protected]

Investor Relations
Mike Callahan / Tom Cook
[email protected]

Canoo Public Relations
[email protected]

GLYFADA, Greece, Dec. 07, 2020 (GLOBE NEWSWIRE) — Globus Maritime Limited (the “Company” or “Globus”) (NASDAQ: GLBS) announced today that it has entered into a securities purchase agreement with certain unaffiliated institutional investors to issue approximately 1.41 million of its common shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 1.27 million common shares at a purchase price of $8.50 per common share and accompanying warrant (or $8.49 per pre-funded warrant and accompanying warrant) in a registered direct offering. The warrants will have an exercise price of $8.50 per share, are exercisable immediately and will expire five and a half years following the date of issuance.

Maxim Group LLC is acting as sole placement agent for the offering.

The gross proceeds to the Company from the offering are estimated to be approximately $12.0 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about December 9, 2020, subject to the satisfaction of customary closing conditions.  

The securities described above are being sold pursuant to a shelf registration statement on Form F-3 (File No. 333-240265), previously filed with the Securities and Exchange Commission (the “SEC”) on July 31, 2020 and declared effective on August 12, 2020. Such securities are being offered only by means of a prospectus. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained at the SEC’s website at www.sec.gov or by contacting Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Globus Maritime Limited

Globus is an integrated dry bulk shipping company that provides marine transportation services worldwide and presently owns, operates and manages a fleet of six dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina and other dry bulk cargoes internationally. Globus’ subsidiaries own and operate six vessels with a total carrying capacity of 381,738 Dwt and a weighted average age of 10.9 years as of September 30, 2020.

Safe Harbor Statement

This communication contains “forward-looking statements” as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons specifically as described in the Company’s filings with the Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Globus undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this communication or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks Globus describes in the reports it will file from time to time with the Securities and Exchange Commission after the date of this communication.

For further information please contact:
Globus Maritime Limited +30 210 960 8300	Capital Link – New York +1 212 661 7566
Athanasios Feidakis, CEO	Nicolas Bornozis
[email protected]	[email protected]

• Continues to scale Mercury’s
  global avionics & mission systems
  business
  
• Complementary capabilities enhance position at forefront of military digital convergence
• Expands platform and mission management content on new and existing airborne platforms
• Broadens mission processing capabilities, adding data transfer and recording solutions
• Leverages investments in embedded security and safety-certifiable avionics processing

ANDOVER, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a leader in trusted, secure mission-critical technologies for aerospace and defense, today announced that it has signed a definitive agreement to acquire Physical Optics Corporation (“POC”). Based in Torrance, Calif., POC is a leading designer, developer, and integrator of advanced technologies primarily focused on avionics & mission subsystems for defense applications.

Pursuant to the terms of the agreement, Mercury will acquire POC for an all-cash purchase price of $310 million, subject to net working capital and net debt adjustments. The acquisition and associated transaction expenses are expected to be funded through a combination of cash on hand and Mercury’s existing revolving credit facility.

POC is currently expected to generate revenue of over $120 million for its fiscal year ending December 31, 2020. The acquisition represents a multiple of approximately 13x next twelve months EBITDA and is expected to be immediately accretive to adjusted EPS.

“The acquisition of Physical Optics Corporation adds important capabilities on new and existing airborne programs in the platform and mission management market,” said Mark Aslett, Mercury’s president and chief executive officer. “The combination of Mercury’s safety-certifiable and secure avionics processing solutions with POC’s deep portfolio of data storage, transfer, and encryption technologies will enable us to deliver more complete, pre-integrated avionics subsystems to our customers. POC has a similar growth profile to Mercury, supported by several key design wins that are transitioning into production. We are very excited for POC to join the Mercury team.”

“This acquisition broadens our avionics product and technology portfolio to help our defense Prime customers, the U.S. Navy, Army and Air Force deploy next-generation open-architecture mission computing solutions,” added Amela Wilson, senior vice president, Mercury Mission. “Similar to Mercury, POC is well-positioned in faster-growing segments of the defense market and benefits from secular growth drivers, such as supply chain delayering. Together, Mercury and POC can provide customers new capabilities and subsystem solutions.”

Founded in 1985, POC employs approximately 350 people, including more than 160 highly skilled engineers, and holds over 160 patents worldwide, covering 60 technologies. They support mission-critical programs with common-use products spanning data transfer systems, flight data recorders, mission computers, high-definition data and video recorders, and advanced encryption devices. POC is well-positioned on a wide variety of key airborne and naval defense platforms that are experiencing increased funding for electronics modernization to specifically address digital convergence and combat near-peer threats in line with the National Defense Strategy.

The acquisition is subject to customary closing conditions, including approval pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is currently expected to close during Mercury’s fiscal 2021 second quarter ending January 1, 2021.

Operating at the intersection of high-tech and defense, Mercury Systems is the leader in making trusted, secure mission-critical technologies profoundly more accessible. Our work is inspired by our Purpose of delivering Innovation That Matters by and for People Who Matter, to make the world a safer, more secure place for all. For more information, visit mrcy.com or contact Mercury at (866) 627-6951 or [email protected].

Mercury Systems – Innovation That Matters

^®


Mercury Systems is a leading technology company serving the aerospace and defense industry, positioned at the intersection of high-tech and defense. Headquartered in Andover, Mass., the Company delivers solutions that power a broad range of aerospace and defense programs, optimized for mission success in some of the most challenging and demanding environments. The Company envisions, creates and delivers innovative technology solutions purpose-built to meet customers’ most-pressing high-tech needs, including those specific to the defense community. To learn more, visit mrcy.com, or follow us on Twitter.

Forward-Looking Safe Harbor Statement

This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the acquisitions described herein and to fiscal 2021 business performance and beyond and the Company’s plans for growth and improvement in profitability and cash flow. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs, the timing and amounts of such funding, general economic and business conditions, including unforeseen weakness in the Company’s markets, effects of epidemics and pandemics such as COVID, effects of any U.S. federal government shutdown or extended continuing resolution, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in, or in the U.S. Government’s interpretation of, federal export control or procurement rules and regulations, market acceptance of the Company’s products, shortages in components, production delays or unanticipated expenses due to performance quality issues with outsourced components, inability to fully realize the expected benefits from acquisitions and restructurings, or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, increases in interest rates, changes to industrial security and cyber-security regulations and requirements, changes in tax rates or tax regulations, changes to interest rate swaps or other cash flow hedging arrangements, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, unanticipated costs under fixed-price service and system integration engagements, and various other factors beyond our control. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended July 3, 2020. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Contact:

Robert McGrail, Director of Corporate Communications
Mercury Systems, Inc.
+1 978-967-1366 / [email protected]

Mercury Systems and Innovation That Matters are registered trademarks of Mercury Systems, Inc. Other product and company names mentioned may be trademarks and/or registered trademarks of their respective holders.

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 16, 2020 from 12pm – 2pm Eastern Time.

This webinar will feature presentations from Key Opinion Leaders (KOLs) Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering, Jaume Mora, M.D., Ph.D., SJD Barcelona Children’s Hospital, and Brian H. Santich, Ph.D., Memorial Sloan Kettering.

• Dr. Modak will discuss DANYELZA^® (naxitamab-gqgk) in combination with chemotherapy;
• Dr. Mora will present updated frontline data for DANYELZA; and
• Dr. Santich will cover the novel SADA Technology Platform (Liquid Radiation^TM) and its potential use across various tumor types

Additionally, Y-mAbs’ management team will also provide updates on DANYELZA in osteosarcoma, ¹⁷⁷Lu-omburtamab-DTPA, omburtamab’s 101 and Diffuse Intrinsic Pontine Glioma (“DIPG”) studies, and the Company’s first bispecific antibody nivatrotamab (GD2xCD3-BsAb) along with a short corporate overview.

Following the formal presentations, Drs. Modak, Mora, and Santich, as well as the Y-mAbs management team will be available to answer questions.

To register for the research and development day, please click here.

Shakeel Modak, M.D., MRCP is a pediatric Hematology-Oncology doctor at Memorial Sloan Kettering Cancer Center, Department of Pediatrics in New York, NY. He received his MBBS and M.D. degrees from TN Medical College, Bombay, as well as his MRCP degree at Royal College of Physicians, London, UK. Dr. Modak specializes in the treatment of children and young adults with neuroblastoma and other solid tumors, such as desmoplastic small round cell tumors (“DSRCT”). He has been named to Best Doctors, New York City for the past seven years in a row. Dr. Modak has been the principal investigator on more than 12 studies initiated and implemented for neuroblastoma and DSRCT. He has also been the co-investigator on over 50 clinical studies.

Jaume Mora, M.D., Ph.D. is the scientific director of the Oncology and Hematology area at SJD Barcelona Children’s Hospital, as well as the director of the Developmental Tumours Laboratory at SJD Barcelona Children’s Hospital. Dr. Mora is a member of different national and international scientific societies, including the International Pediatric Oncology Society, which has awarded him the Schweisguth Prize, and the American Society of Clinical Oncology (“ASCO”), which in 2000 honored him with the young investigator award (YIA), as well as the Career Development Award (“CDA”). In 2011, Dr. Mora was the recipient of the annual BBVA Foundation Award and in 2006 was awarded the First Prize from the Spanish Association Against Cancer (“AECC”) for his work in childhood cancers.

Brian H. Santich, Ph.D. is Research Fellow at the Nai-Kong Cheung Lab at Memorial Sloan Kettering Cancer Center and is an experienced PhD scientist with 10 years of training in antibody engineering, T-cell immunotherapy, targeted radionuclide therapy and immunology. His work has spanned many diseases including cancer (neuroblastoma, small-cell lung cancer), viral infections (HIV, dengue virus), and primary immunodeficiencies (chronic granulomatous disease). Brian’s research projects have ranged from antibody discovery campaigns (phage display, yeast display), humanizations, lead optimization, lab scale manufacturing and purification, to functional validation (in vitro and in vivo) and IND-enabling toxicology studies. His work helped facilitated the successful IND application for nivatrotamab, as well as spearheaded the development of the novel targeted radionuclide therapy platform, SADA. Over the past five years, Brian has filed 11 patents and written three first author manuscripts.

Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests related to the compound and Y-mAbs.

About DANYELZA® (naxitamab-gqgk)

DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.

About
Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product portfolio and pipeline, including one FDA approved product, DANYELZA^® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets B7-H3.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development and commercialization plans; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘hope,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘possibility,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in our Annual Report on Form 10-K and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

“DANYELZA” and “Y-mAbs” are registered trademarks of Y-mAbs Therapeutics, Inc.

Contact:

Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA

+1 646 885 8505

E-mail: [email protected]

Tysons, VA and Phoenix, AZ, Dec. 07, 2020 (GLOBE NEWSWIRE) — Cvent, a market-leading meetings, corporate travel, and hospitality technology provider, and BWH Hotel Group today announced a major, 10-year agreement for Cvent Transient solutions. Under the agreement, BWH Hotel Group will use Cvent’s transient sourcing platform to set and promote corporate hotel rates and manage RFPs from the world’s largest corporations for more than 4,700 properties worldwide.  

 

The deal comes after Cvent announced enhanced functionality and a streamlined user experience for Cvent RFP Publisher® and other products within the Cvent Transient solutions suite at its customer conference, Cvent CONNECT, in August.  Since acquiring Lanyon, Cvent has made significant investments in its transient platform to support both buyers and suppliers in an increasingly dynamic travel environment.  The long-term partnership with BWH Hotel Group, which spans the entire decade starting in 2021, reflects Cvent’s continued commitment to deliver innovative solutions that meet the evolving needs of hotels seeking to grow their corporate travel business.

 

“We are pleased to partner with Cvent, a proven leader that understands the market, can support the needs of our diverse portfolio of hotels, and prioritizes innovation and customer success,” said Dorothy Dowling, chief marketing officer of BWH Hotel Group. “At BWH Hotel Group, we believe the effective application of technology is essential to our long-term success in the business transient segment, and we know that Cvent is a company we can count on to support that success over the next decade.” 

 

“A deal of this duration and magnitude reflects our two companies’ confidence in the future of business travel,” said Reggie Aggarwal, CEO and founder of Cvent. “Given the current environment, we understand how critical corporate travel will be as the industry recovers. With our continued investment in the transient space and our deep industry expertise, this partnership with BWH Hotel Group highlights our unique ability to help hotels achieve success in the business transient segment. We appreciate BWH Hotel Group’s continued support, and we look forward to helping them thrive for years to come.” 

###

 

About Cvent

Cvent is a leading meetings, events, and hospitality technology provider with nearly 4,000 employees, 30,000 customers, and 300,000 users worldwide. Founded in 1999, the company delivers the most comprehensive event marketing and management platform and offers a global marketplace where event professionals collaborate with venues to create unmatched experiences. The comprehensive Cvent event marketing and management platform offers software solutions to event organizers and marketers for online event registration, venue selection, event marketing and management, virtual and onsite solutions, and attendee engagement. Cvent’s suite of products automate and simplify the entire event management process and maximize the impact of in-person, virtual, and hybrid events.  Hotels and venues use Cvent’s supplier and venue solutions to win more group and corporate travel business through Cvent’s sourcing platforms and to service their customers directly, efficiently and profitably – helping them grow and own their business. Cvent solutions optimize the entire event management value chain and have enabled clients around the world to manage millions of meetings and events. For more information, please visit Cvent.com, or connect with us on Facebook, Twitter or LinkedIn.

  

About BWH Hotel Group®

BWH Hotel Group is a leading, global hospitality network comprised of three hotel companies, including WorldHotels® Collection, Best Western® Hotels & Resorts and SureStay Hotel Group®. BWH Hotel Group serves as the umbrella parent organization to each hotel company, bringing a full-suite of options to travelers, while also protecting the unique identity of each brand. This creates a global network of approximately 4,700 hotels across every chain scale segment, in over 100 countries and territories worldwide.

 

Erica Stoltenberg
Cvent
5713786240
[email protected]

CHARLOTTE, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — LPL Financial LLC (Nasdaq:LPLA), a leading retail investment advisory firm, independent broker-dealer and registered investment advisor (RIA) custodian, today announced that Rosemont Financial Group has joined LPL Financial’s broker-dealer and corporate RIA platforms, leveraging LPL as custodian. The advisors reported having served approximately $900 million in advisory, brokerage and retirement plan assets*. They join LPL from Cambridge Investment Research Advisors.

Rosemont was created in 2010 by five associates of a global financial firm looking to bring added value, experience and teamwork to both their existing client base and potential new clients. The Albany, N.Y.-based team has grown to include 11 financial advisors: President Steven Novotny, CFP^®, Vice President Paul Coluccio, CFP^®, René. Farrington, AIF, CFP^®, Christopher Gilbert, Cody Wojdyla CFP^®, Judith Odell, CPA, Ross Fábregas, Joseph Turo, CPA, Christopher Dacey, Lorraine Reith, and Christopher Noonan, AIF. They are supported by a trading assistant and a five-member office support team, which includes two accountants.

The Rosemont team offers comprehensive wealth management and financial planning to corporations, families and individuals with a mission to help clients “gain through confidence,” a tagline for the business. The firm provides a range of services including investment analytics, executive compensation, portfolio management, retirement planning and estate planning, as well as tax assistance from the firm’s CPAs.

Covid-19 prompted the firm to look for a new partner. Novotny stated, “With more clients at home, looking to access their information online or through conference calls, we recognized the need to find a partner that offers enhanced technology. LPL stood out as an industry leader, with an online portal that is easy for our clients to use and navigate. And for our advisors, with everything integrated into one platform, it’s easier to manage our business and put more time toward working with our clients.”

Additionally, Novotny said the fact that LPL is self-clearing allows the team to save time and costs. He also appreciates LPL’s in-depth research that he can use to help clients make more sense of the financial landscape and investment strategies.

“We welcome the entire Rosemont team to the LPL family,” said Rich Steinmeier, LPL Financial managing director and divisional president, Business Development. “Advisors have demonstrated a remarkable commitment to clients this year, even as they moved to a virtual role. But the experiences of this year shined even more light on the role technology, digital capabilities and partnership play in an advisor’s practice. Advisors need robust resources to differentiate the client experience and to manage a resilient practice. We will continue to invest in the capabilities and solutions that help advisors grow value with their clients and for their business. We look forward to a long-lasting relationship with Rosemont Financial Group.”

Read about other firms that recently joined LPL in the LPL Financial News and Media section of LPL.com.

Advisors, find an LPL business development representative near you.

About LPL Financial

LPL Financial (https://www.lpl.com) is a leader in the retail financial advice market, the nation’s largest independent broker-dealer** and a leading custodian (or provider of custodial services) to RIAs. We serve independent financial advisors, professionals and financial institutions, providing them with the technology, research, clearing and compliance services, and practice management programs they need to create and grow thriving practices. LPL enables them to provide objective guidance to millions of American families seeking wealth management, retirement planning, financial planning and asset management solutions.

*Based on prior business and represents assets that would have been custodied at LPL Financial, rather than third-party custodians. Reported assets and client numbers have not been independently and fully verified by LPL Financial.

**Based on total revenues, Financial Planning magazine June 1996-2020.

Securities and advisory services offered through LPL Financial LLC, an SEC- registered broker-dealer and investment advisor. Member FINRA/SIPC. 

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial LLC. We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

Rosemont Financial Group and LPL Financial are separate entities. Tax and Accounting related services are offered through Rosemont Financial Group. LPL Financial does not offer tax advice or accounting related services.

Connect with Us!

https://twitter.com/lpl

https://www.linkedin.com/company/lpl-financial

https://www.facebook.com/LPLFinancialLLC

https://www.youtube.com/user/lplfinancialllc

Media Contact:


Lauren Hoyt-Williams
(980) 321-1232
[email protected] 

MAYNARD, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Stratus Technologies, a global leader in simplified, protected, autonomous Edge Computing platforms, today launched enhancements to its ztC Edge computing platform with the release of Stratus Redundant Linux (SRL) version 2.2 and a preview of a new, comprehensive edge systems management solution, ztC™ Advisor. These enhancements enable optimal infrastructure performance, utilization, and faster time-to-value to ensure simple, protected, and autonomous business operations.

Stratus Redundant Linux 2.2, ztC Edge’s core operating system, features an enhanced application interface, REST API, that provides more information via the web about ztC Edge’s virtual machines (VMs) and their current state. This capability allows teams to remotely optimize infrastructure performance and utilization. SRL 2.2 also includes additional software and security updates.

ztC Advisor:
Comprehensive
Remote
System
s
Management

With ztC Advisor, Stratus introduces a new edge systems management solution to simplify centralized monitoring and management of a customer’s entire ztC Edge computing infrastructure. The new solution offers a secure web-based portal that anyone in operations or IT can use to quickly and easily view the health and utilization of their entire ztC Edge inventory, remotely triage issues, improve productivity, and mitigate risk.

“These ztC Edge platform enhancements, including the introduction of ztC Advisor, represent our continued investment in edge innovation as well as our commitment to deliver simple, protected, and autonomous zero-touch Edge Computing solutions,” said Jason Andersen, Vice President of Business Line Management at Stratus. “With ztC Advisor, we are simplifying how customers manage their fleet of ztC Edge platforms – and they don’t need to be operations or IT experts. Customers point to the availability of comprehensive edge management tools and dashboards that anyone can use as critical to their success.”

Customers
Quotes about
ztC Advisor

• “With a clean, user-friendly dashboard, ztC Advisor helps us efficiently monitor and manage our growing multi-ztC Edge environment,” said Andreas Linn, Support Manager, Nonstop Technologies GmbH

• “Because it’s so easy to set up and use, ztC Advisor helps admins of all backgrounds become productive quickly,” said Hans-Jürgen Rux, Consultant/Analyst, DIVENTUS GmbH

• “With an intuitive interface, ztC Advisor is very easy to use – for admins of all backgrounds,” said David Edwards, Cybersecurity Systems Engineer, Velta Technology

Released as a preview, ztC Advisor’s first features include:

• A c
  omprehensive asset management
  overview of all ztC Edge platforms owned by a customer, including systems that have been deployed but have not been provisioned. The overview makes it easier for administrators to holistically maximize resource utilization and optimize their hardware refresh and software patching schedules.

• A centralized
  dashboard view of individual system status and resource utilization presented in real-time, enabling administrators to easily see platform status at-a-glance.

• User
  –
  defined groups for customers to assign individual systems to groups and use the ztC Advisor dashboard’s built-in sorting and filtering functions to quickly access information from specific platforms. 

• Secure
  –
  push technology between ztC Advisor and ztC Edge. The web-based solution is architected so that ztC Edge platforms initiate sessions and periodically push information to ztC Advisor which minimizes cyber-security risk by limiting data transfer.

• Integration with Stratus Service Portal and ztC Edge platforms
  , allowing customers with portal access to use their same credentials to access ztC Advisor. One-click enablement from the ztC Edge Console automatically sets up the corresponding ztC Edge platform to be visible and present data through ztC Advisor, minimizing setup and configuration time.

ztC Advisor and its remote system monitoring capabilities are compatible with ztC Edge platforms running SRL 2.2, and build updates to ztC Edge platforms, released early last year, that address customers’ most pressing needs for enhanced security, monitoring and performance at the edge.

About
ztC Edge

The Stratus ztC™ Edge is a secure, rugged, highly automated Edge Computing platform that helps increase operational efficiency and eliminate downtime by simplifying and protecting business-critical applications.

Purpose-built for operational technology (OT) while meeting standard IT performance and security requirements, ztC Edge is simple to deploy, protected from interruptions and threats, and operates autonomously. The zero-touch Edge Computing platform can be quickly installed at a single location or across multiple locations without the need for specialized IT skills.

ztC Edge is a proven computing platform that has helped Stratus customers across many industries reduce their operations and maintenance costs, minimize risk of data loss, and ensure continuous availability for business-critical operations.

About Stratus

For leaders digitally transforming their operations to drive predictable, peak performance with minimal risk, Stratus ensures the continuous availability of business-critical applications by delivering zero-touch Edge Computing platforms that are simple to deploy and maintain, protected from interruptions and threats, and autonomous. For 40 years, we have provided reliable and redundant zero-touch computing, enabling global Fortune 500 companies and small-to-medium sized businesses to securely and remotely turn data into actionable intelligence at the Edge, cloud and data center – driving uptime and efficiency. For more information, please visit www.stratus.com or follow on Twitter @StratusAlwaysOn and LinkedIn @StratusTechnologies

Press Contacts

DoShik Wood
[email protected]
+1 978-461-7064

Dominique Todd
[email protected]
+1 978-461-7144

 

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — MineralTree President Vijay Ramnathan will participate in a virtual panel tomorrow with Ardent Partners’ research team to discuss key market trends and predictive scenarios for the year ahead. The event, Accounts Payable 2021: Big Trends and Predictions, is part of Ardent’s quarterly AP webinar series and takes place at 2:00 pm ET on December 9^th.

The accounts payable industry is consistently evolving and shifting, forcing AP and finance professionals across the globe to prepare for change and innovation in technology, business regulations, and the general speed of commerce. This webinar is an ideal “stage-setting” event for AP and finance professionals as they move into 2021.

Accounts Payable 2021: Big Trends and Predictions
	Weds., Dec. 9, 2020, 2:00 – 3:00 pm ET
	Speakers:
	•  Bob Cohen, Vice President of Research, Ardent Partners •  Vijay Ramnathan, President, MineralTree •  Andrew Bartolini, Chief Research Officer, Ardent Partners

To Register:

https://cporising.com/accounts-payable-2021-big-trends-and-predictions/

MineralTree Resources:

Industry Report: The State of AP 2020: A Research Report
Product Overview: End-to-End AP Automation – How it Works

About MineralTree

MineralTree provides modern, secure, easy-to-use, end-to-end Accounts Payable (AP) Automation solutions that reduce costs by more than 75%, increase visibility and control, and mitigate fraud and risk, while improving cash flow. More than 3,000 mid-market and mid-enterprise companies, as well as more than 30 financial institutions rely on MineralTree to digitize and optimize the entire AP Automation and Payments process, preserving control over the complete invoice-to-payment workflow, improving vendor relationships, maximizing ROI, and transforming the finance function from a cost center to a profit center. For more information, visit https://www.mineraltree.com.

Media Inquiries
Tim Walsh
for MineralTree, Inc.
617.512.1641
[email protected]

CALABASAS, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — MusclePharm Corporation (OTCMKTS: MSLP) (the “Company”), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today announced that the Company has retained ICR, Inc., a leading strategic communications and advisory firm, to assist with its investor relations program.

Ryan Drexler, President and Chief Executive Officer, stated, “We are very excited to be working with a distinguished communications firm like ICR to build out our investor relations program and help position our Company. The past few years have been spent restructuring the Company and strengthening our leading brands and we believe ICR will be instrumental in broadening our reach with the investment community and increasing our public profile with shareholders.”

About
MusclePharm
, Inc.

MusclePharm® is an award-winning, worldwide leading sports nutrition & lifestyle company offering branded nutritional supplements. Its portfolio of recognized properties include the MusclePharm® Sport Series, Essentials Series, Natural Series, and FitMiss™ – a product line designed specifically for female athletes. MusclePharm® products are available in more than 100 countries globally, with its Combat Protein product lineup being the company’s most popular.

About ICR, Inc.

Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 750 clients in approximately 20 industries. ICR’s healthcare practice operates under the Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore, San Francisco, San Diego and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.

FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements, such as those regarding ICR’s expected impact on the Company’s profile with shareholders and the investment community, within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical facts, regarding MusclePharm’s expectations, strategies, prospects or targets are forward-looking statements.  These forward-looking statements also can be identified by the use of forward-looking terminology such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plan,” “predict,” “project,” or “will,” or the negative of these terms or other comparable terminology.  

These forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties that could cause our actual results to differ materially from those projected including: the duration of the COVID-19 pandemic and the extent and length of the shelter-in and other restrictions associated with COVID-19 pandemic.

Forward-looking statements are made only as of the date hereof.  Except as otherwise required by law, we assume no obligation to update any of the forward-looking statements contained in this press release.

Contact:

John Mills, Managing Partner
ICR, Inc.
646-277-1254
[email protected]